Association of transdermal fentanyl and oral transmucosal fentanyl citrate in the treatment of opioid naïve patients with severe chronic noncancer pain

Francisco Collado, MD, PhD; Luis M. Torres, MD, PhD

doi:10.5055/jom.2008.0016

Authors

Francisco Collado, MD, PhD
Luis M. Torres, MD, PhD

DOI:

https://doi.org/10.5055/jom.2008.0016

Keywords:

pain/drug therapy, fentanyl/ administration & dosage, fentanyl/adverse effects, chronic disease/drug therapy, analgesics/opioid

Abstract

Background: Chronic noncancer pain is often undertreated.
Aims: To assess the efficacy of fentanyl transdermal therapeutic system (TTS) associated with oral transmucosal fentanyl citrate (OTFC) for breakthrough pain in patients with chronic noncancer pain.
Methods: A total of 215 patients with chronic (≥6 months), severe (VAS ≥ 8) noncancer pain participated in a 6-month prospective study. The starting dose of 12 μg/h fentanyl TTS was titrated in 25 μg/h increments to a visual analog scale (VAS) score ≤ 4. OTFC was administered as single-unit doses of 400 μg.
Results: The mean (SD) VAS score decreased from 9.86 (0.35) at baseline to 2.05 (0.96) at 6 months. The percentage of patients with poor quality of sleep decreased from 99 percent at baseline to 2.8 percent at the end of the study. The percentage of patients with inadequate pain control decreased from 16.2 percent at month 1 to 2.3 percent at month 6. Pain control was achieved with the 50 μg/h dose in 48 percent of patients, the 75 μg/h dose in 18 percent, and the 100 μg/h dose in 5 percent (only two patients required >100 μg/h). The daily use of single-unit doses of OTFC decreased from 4.64 at month 1 to 2.62 at month 6. Headache, nausea/vomiting, constipation, and somnolence of mild or moderate intensity were the most common side effects. Treatment was discontinued because of nausea/vomiting in seven patients, somnolence in three, and dermatitis in two.
Conclusions: Fentanyl TTS associated with OTFC for breakthrough pain is a feasible and effective strategy in opioid naïve patients with severe chronic nonmalignant pain.

Author Biographies

Francisco Collado, MD, PhD

F.E.A. Pain Clinic; Department of Anesthesiology-Critical Care and Pain Management, Cádiz University, Cádiz, Spain.

Luis M. Torres, MD, PhD

Head of Department of Anesthesiology-Critical Care and Pain Management), University Hospital Puerta del Mar, Cádiz, Spain.

References

Gureje O, Von Korff M, Simon GE, et al.: Persistent pain and well being. A World Health Organization Study in primary care. JAMA. 1998; 280: 147-151.

Reid MC, Engles-Horton LL, Weber MB, et al.: Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med. 2002; 17: 173-179.

Clark JD: Chronic pain prevalence and analgesic prescribing in a general medical population. J Pain Symptom Manage. 2002; 23: 131-137.

Bannwarth B: Risk-benefit assessment of opioids in chronic noncancer pain. Drug Safety. 1999; 21: 283-296.

Jage J: Opioid tolerance and dependence—Do they matter? Eur J Pain. 2005; 9: 157-162.

Kahan M, Srivastava A, Wilson L, et al.: Misuse and dependence on opioids. Can Fam Physician. 2006; 52: 1081-1087.

Breivik H, Collett B, Ventafrida V, et al.: Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment. Eur J Pain. 2006; 10: 287-333.

World Health Organization: Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organization Technical Report Series (second edition). Geneva, Switzerland, WHO, 1996.

Torres LM, Calderón E, Pernia A, et al.: De la escalera al ascensor. Rev Soc Esp Dolor. 2002; 9: 289-290.

Mystakidou K, Tsilika E, Parpa E, et al.: Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer. 2003; 107: 486-492.

Furlan AD, Sandoval JA, Mailis-Gagnon A, et al.: Opioids for chronic noncancer pain: A meta-analysis of effectiveness and side effects. Canadian Med Assoc J. 2006; 174: 1589-1594.

Milligan K, Lanteri-Minet M, Borchert K, et al.: Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain. 2001; 2: 197-204.

Kornick CA, Santiago-Palma J, Moryl N, et al.: Benefit-risk assessment of transdermal fentanyl for the treatment of chronic pain. Drug Safety. 2003; 26: 951-973.

Clark AJ, Ahmedzai SH, Allan LG, et al.: Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain. Curr Med Res Opin. 2004; 20: 1419-1428.

Allan L, Richarz U, Simpson K, et al.: Transdermal fentanyl versus sustained release oral morphine in strong-opioid naïve patients with chronic low back pain. Spine. 2005; 30: 2484-2490.

Otis J, Rothman M: A phase III study to assess the clinical utility of low-dose fentanyl transdermal system in patients with chronic non-malignant pain. Curr Med Res Opin. 2006; 22: 1493-1501.

Langford R, McKenna F, Ratcliffe S, et al.: Transdermal fentanyl for improvement of pain and functioning in osteoarthritis: A randomized, placebo-controlled trial. Arthritis Rheum. 2006; 54: 1829-1837.

Fine PG, Streisand JB: A review of oral transmucosal fentanyl citrate: Potent, rapid and non-invasive opioid analgesia. J Palliat Med. 1998; 1: 55-63.

Farrar JT, Cleary J, Rauck R, et al.: Oral transmucosal fentanyl citrate: Randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst. 1998; 90: 611-616.

Coluzzi PH, Schwatzberg L, Conroy JD Jr, et al.: Breakthrough cancer pain: A randomized trial comparing oral transmucosal fentanyl citrate (OTFC®) and morphine sulfate immediate release (MSIR®). Pain. 2001; 91: 123-130.

Freynhagen RM, Jürgen von Giesen H, Busche P, et al.: Switching from reservoir to matrix systems for the transdermal delivery of fentanyl: A prospective, multicenter pilot study in outpatients with chronic pain. J Pain Symptom Manage. 2005; 30: 289-297.

Christie JM, Simmonds M, Patt R, et al.: Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol. 1998; 16: 3238-3245.

Trelis J, Pérez-Hernández C, Sánchez-Domínguez F, et al.: Transmucosal oral fentanyl citrate for the management of irruptive pain suffered by cancer patients in Spain: Results of the EDIPAD study. [Article in Spanish]. Rev Soc Esp Dolor. 2004; 11: 184-196.

Cepeda MS, Farrar JT, Baumgarten M, et al.: Side effects of opioids during short-term administration: Effect of age, gender, and race. Clin Pharmacol Ther. 2003; 74: 102-112.

Wilder-Smith OHG: Opioid use in the elderly. Eur J Pain. 2005; 9: 137-140.

Donner B, Zenz M, Tryba M, et al.: Direct conversion from oral morphine to transdermal fentanyl: A multicenter study in patients with cancer pain. Pain. 1996; 64: 527-534.

Ackerman SJ, Knight T, Schein J, et al.: Risk of constipation in patients prescribed fentanyl transdermal system or oxycodone hydrochloride controlled-release in a California Medicaid population. Consult Pharm. 2004; 19: 118-132.

Ahmedzai S, Brooks D, on behalf of the TTS-Fentanyl Comparative Trial Group: Transdermal fentanyl versus sustainedrelease oral morphine in cancer pain: Preference, efficacy, and quality of life. J Pain Symptom Manage. 1997; 13: 254-261.

Sabatowski R, Schwalen S, Rettig K, et al.: Driving ability under long-term treatment with transdermal fentanyl. J Pain Symptom Manage. 2003; 25: 38-47.

Menefee LA, Frank ED, Crerand C, et al.: The effects f transdermal fentanyl on driving, cognitive performance, and balance in patients with chronic nonmalignant pain conditions. Pain Med. 2004; 5: 42-49.

Zeppetella G, Ribeiro MD: Opioids for the management of breakthrough (episodic) pain in cancer patients. Cochrane Database Syst Rev. 2006; 1: CD004311.

Mystakidou K, Katsoude E, Parpa E, et al.: Oral transmucosal fentanyl citrate: Overview of pharmacological and clinical characteristic. Drug Deliv. 2006; 13: 269-276.